Insights
Search Results
News Articles
6.04.26
Wilson Sonsini Practices, Attorneys Recognized in 2026 Chambers USA Guide
The 2026 Chambers USA guide has recognized Wilson Sonsini Goodrich & Rosati as a leading law firm in 44 geography-specific practice categories and named 87 Wilson Sonsini attorneys among the best in their fields. This year, the firm received four new practice area rankings, including in the nationwide National Security and Capital Markets: Convertible Debt categories, and three improved practice area rankings.
Case Studies
2.24.26
How Wilson Sonsini Helped Foresight Diagnostics with Its Growth, Scale-Up, and Acquisition
Foresight Diagnostics is a leading cancer diagnostics company founded in 2020 and spun out of Stanford University. Foresight has developed a novel liquid biopsy testing platform for the measurement of minimal residual disease that is significantly more sensitive than existing tests. Its technology, called PhasED-SeqTM, is based on a simple blood draw and next-generation sequencing. It is broadly applicable to a variety of cancers, and its ability to detect circulating tumor DNA at levels of 0.0001 percent (or one part-per-million) has the potential to provide actionable information to physicians and biopharmaceutical companies, thus enabling the development of a more proactive and personalized treatment approach.
Client Highlights
2.23.26
Firm Advises Arcellx on $7.8 Billion Acquisition by Gilead
On February 23, 2026, Gilead Sciences announced that it has entered into a definitive agreement to acquire Arcellx, a biotechnology company focused on delivering a new class of innovative immunotherapies for patients with cancer and other incurable diseases, for $115 per share in cash at closing and one contingent value right of $5 per share, which represents an implied equity value of $7.8 billion payable at closing. Wilson Sonsini Goodrich & Rosati advised Arcellx on the transaction.
Client Highlights
2.06.26
Wilson Sonsini Advises PacBio on Sale of Short-Read DNA Sequencing Assets
On February 2, 2026, PacBio, a leading developer of high-quality, highly accurate sequencing solutions, announced the completion of the sale of select intellectual property and other assets related to PacBio’s short-read DNA sequencing technology and related clustering, sequencing reagent, and detection technologies to Illumina, Inc. PacBio received approximately $50 million in cash proceeds from the transaction. Wilson Sonsini Goodrich & Rosati advised PacBio on the transaction.
Client Highlights
2.05.26
Wilson Sonsini Advises SpyGlass Pharma on $150 Million IPO
On February 5, 2026, SpyGlass Pharma, Inc., a late-stage biopharmaceutical company, announced the pricing of its initial public offering of 9,375,000 shares of its common stock at a public offering price of $16.00 per share. The aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by SpyGlass Pharma, are expected to be approximately $150 million. Wilson Sonsini Goodrich & Rosati advised SpyGlass Pharma on the transaction.
SpyGlass Pharma has granted the underwriters a 30-day option to purchase up to an additional 1,406,250 shares of common stock at the initial public offering price, less underwriting discounts and commissions. All shares of common stock are being offered by SpyGlass Pharma. SpyGlass Pharma’s common stock is expected to begin trading on the Nasdaq Global Select Market on February 6, 2026, under the ticker symbol “SGP.” The offering is expected to close on February 9, 2026, subject to the satisfaction of customary closing conditions.
The Wilson Sonsini team that advised SpyGlass Pharma includes:
SpyGlass Pharma has granted the underwriters a 30-day option to purchase up to an additional 1,406,250 shares of common stock at the initial public offering price, less underwriting discounts and commissions. All shares of common stock are being offered by SpyGlass Pharma. SpyGlass Pharma’s common stock is expected to begin trading on the Nasdaq Global Select Market on February 6, 2026, under the ticker symbol “SGP.” The offering is expected to close on February 9, 2026, subject to the satisfaction of customary closing conditions.
The Wilson Sonsini team that advised SpyGlass Pharma includes:
Client Highlights
1.12.26
Wilson Sonsini Advises on Juvena Therapeutics on IP Matters Related to $33.5 Million Series B
On January 12, 2026, Juvena Therapeutics, a clinical-stage biotechnology company whose AI-enabled regenerative biologics are designed to restore tissue function, announced its $33.5 million Series B. The financing round was led by Bison Ventures with participation from Eli Lilly and Company, Jefferson Life Sciences, and existing institutional backers including Mubadala Capital and Manta Ray. Wilson Sonsini Goodrich & Rosati advised Juvena on IP matters related to the transaction.
Client Highlights
12.08.25
Wilson Sonsini Advises Foresight Diagnostics on Acquisition by Natera
On December 5, 2025, Natera, Inc., a global leader in cell-free DNA and precision medicine, and Foresight Diagnostics, a leader in ultrasensitive molecular residual disease (MRD) detection, announced that Natera has completed its acquisition of Foresight in an all-stock transaction consisting of a $275 million upfront payment with an additional $175 million in earnouts tied to the achievement of revenue- and reimbursement-based milestones. Wilson Sonsini Goodrich & Rosati advised Foresight on the transaction.
The transaction combines Natera’s leading commercial and operational infrastructure for the delivery of personalized MRD testing with Foresight’s unique phased variant technology and leadership in lymphoma. It builds on Natera’s broad intellectual property portfolio for tumor-informed and personalized MRD products including in phased variants, and promises to accelerate MRD adoption in lymphoma and other solid tumor types.
The transaction combines Natera’s leading commercial and operational infrastructure for the delivery of personalized MRD testing with Foresight’s unique phased variant technology and leadership in lymphoma. It builds on Natera’s broad intellectual property portfolio for tumor-informed and personalized MRD products including in phased variants, and promises to accelerate MRD adoption in lymphoma and other solid tumor types.
Client Highlights
11.18.25
Firm Advises ABL Bio on Strategic Alliance and Equity Investment with Eli Lilly
On November 14, 2025, ABL Bio announced a broad strategic research and development alliance with Eli Lilly and Company, establishing a multi-program collaboration to advance next-generation therapeutics using ABL Bio’s Grabody Platform. Wilson Sonsini Goodrich & Rosati advised ABL Bio on the license, research, and collaboration agreement, which is valued at up to $2.602 billion, including a $40 million upfront payment. Through this partnership, ABL Bio and Lilly will jointly explore and develop multiple therapeutic modalities across a range of disease areas, marking a significant expansion of ABL Bio’s platform-driven global collaborations.
Client Highlights
11.10.25
Wilson Sonsini Advises Iambic on Oversubscribed $100 Million Financing
On November 10, 2025, Iambic, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, announced that it has raised approximately $100 million in an oversubscribed financing round. Wilson Sonsini Goodrich & Rosati advised Iambic on the transaction.
News Articles
10.01.25
LMG Life Sciences Recognizes Wilson Sonsini, Attorneys in 2025 Guide
On September 30, 2025, LMG Life Sciences announced the 2025 edition of its guide, which identifies and ranks the leading law firms and individuals in the life sciences industry across the United States. The rankings are the result of firm participation in questionnaires, partner interviews to gather market feedback, client surveys, and independent research. LMG Life Sciences has conducted research and published rankings since 2012. This year, six Wilson Sonsini practices and 18 attorneys have been recognized in the guide.
Client Highlights
9.04.25
Wilson Sonsini Advises Foresight on Roche Settlement and Licensing Agreement
On August 29, 2025, Foresight Diagnostics, a privately held cancer diagnostics company and CLIA-registered laboratory, announced that it has entered into a limited licensing agreement with Roche Molecular Systems and Roche Sequencing Systems (together, Roche) involving Foresight’s patented PhasED-Seq™ technology. The agreement resolves litigation between the parties, with all claims against Foresight, its founders, and Stanford University dismissed with prejudice. Wilson Sonsini Goodrich & Rosati advised Foresight on the settlement and licensing agreement.
Client Highlights
8.13.25
Firm Advises Kumquat on Exclusive $1.3 Billion Global License and Collaboration with Bayer
On August 12, 2025, Kumquat Biosciences Inc., a clinical-stage biotechnology company dedicated to developing life-saving cancer therapies, announced that it has entered into an exclusive global license and collaboration agreement with Bayer to develop and commercialize Kumquat’s KRAS G12D inhibitor. Under the agreement, Kumquat will initiate and complete a Phase Ia clinical study, while Bayer will lead later-stage development and commercialization activities. Wilson Sonsini Goodrich & Rosati represented Kumquat in the transaction.